NON-VAL30MET-TRANSTHYRETIN AMYLOID CARDIOMYOPATHY. LITERATURE REVIEW AND CLINICAL CASE
A. Ya. Gudkova,
A. A. Poliakova,
А. V. Amelin,
O. М. Moiseeva,
А. N. Krutikov,
V. М. Tishkova,
R. V. Grozov,
D. V. Ryzhkova,
T. V. Makurova,
A. A. Kostareva,
E. N. Semernin,
E. V. Shlyakhto https://doi.org/10.15829/1560-4071-2018-2-121-128
Abstract
A literature review presented, with a clinical observation of non-Val30Mettransthyretin amyloid cardiomyopathy. Modern diagnostic and management algorithms discussed.
About the Authors
A. Ya. Gudkova
Federal Almazov North-West Medical Research Centre of the Ministry of Health; Pavlov First Saint-Petersburg State Medical University of the Ministry of Health
Russian Federation
Gudkova Alexandra Ya.
Russian Federation
Gudkova Alexandra Ya.
A. A. Poliakova
Federal Almazov North-West Medical Research Centre of the Ministry of Health; Pavlov First Saint-Petersburg State Medical University of the Ministry of Health
Russian Federation
Russian Federation
А. V. Amelin
Pavlov First Saint-Petersburg State Medical University of the Ministry of Health
Russian Federation
Russian Federation
O. М. Moiseeva
Federal Almazov North-West Medical Research Centre of the Ministry of Health
Russian Federation
Russian Federation
Saint-Petersburg
А. N. Krutikov
Federal Almazov North-West Medical Research Centre of the Ministry of Health
Russian Federation
Russian Federation
Krutikov Аleksandr N.
Saint-Petersburg
V. М. Tishkova
Federal Almazov North-West Medical Research Centre of the Ministry of Health
Russian Federation
Russian Federation
Tishkova Vera М.
Saint-Petersburg
R. V. Grozov
Federal Almazov North-West Medical Research Centre of the Ministry of Health
Russian Federation
Russian Federation
Grozov Roman V.
Saint-Petersburg
D. V. Ryzhkova
Federal Almazov North-West Medical Research Centre of the Ministry of Health
Russian Federation
Russian Federation
Ryzhkova Darya V.
Saint-Petersburg
T. V. Makurova
Federal Almazov North-West Medical Research Centre of the Ministry of Health
Russian Federation
Makurova Tatyana V.
Russian Federation
Makurova Tatyana V.
A. A. Kostareva
Federal Almazov North-West Medical Research Centre of the Ministry of Health; Pavlov First Saint-Petersburg State Medical University of the Ministry of Health
Russian Federation
Kostareva Anna А.
Russian Federation
Kostareva Anna А.
E. N. Semernin
Federal Almazov North-West Medical Research Centre of the Ministry of Health; Pavlov First Saint-Petersburg State Medical University of the Ministry of Health
Russian Federation
Semernin Evgeny N.
Russian Federation
Semernin Evgeny N.
E. V. Shlyakhto
Federal Almazov North-West Medical Research Centre of the Ministry of Health; Pavlov First Saint-Petersburg State Medical University of the Ministry of Health
Russian Federation
Shlyakhto Evgeny V.
Russian Federation
Shlyakhto Evgeny V.
References
1. Haleakala AD, Gilmore JD, Hawkins PN. System amyloidosis. Lancet 2016; 387: 2641-54. DOI: 10.1016/S0140-6736(15)01274.
2. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des. 2008; 14 (30): 3219-30. DOI: 10.2174/138161208786404155.
3. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agencyapproved drug. J Mol Biol. 2012; 421 (2-3): 185-203. DOI:10.1016/j.jmb.2011.12.060.
4. Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34 (19): 1448-58. DOI: 10.1093/eurheartj/ehs397.
5. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011; 10: 1086-97. DOI: 10.1016/S1474-4422(11)70246-0.
6. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010; 7 (7): 398-408. DOI: 10.1038/nrcardio.2010.67.
7. Sekijima Y, Yoshida K, Tokuda T, et al. Familial Transthyretin Amyloidosis. In: Pagon RA, Bird TD, Dolan CR, et al. ed. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle: 1993-2018. ISSN: 2372-0697
8. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 8: 31-49. DOI: 10.1186/1750-1172-8-31.
9. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014; 35: 2733-79. DOI:10.1093/eurheartj/ehu284.
10. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97 (1): 75-84. DOI: 10.1136/hrt.2009.190405.
11. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133: 2404-12. DOI: 10.1161/CIRCULATIONAHA.116.021612.
12. Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med. 2010; 134: 545-51. DOI: 10.1043/1543-2165-134.4.545.
13. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002; 346 (23): 1786-91. DOI: 10.1056/NEJMoa013354.
14. Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006; 107 (9): 3489-91. DOI: 10.1182/blood-200510-4148.
15. Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016; 29 (Suppl. 1): S14-S26. DOI: 10.1097/WCO.0000000000000289.
16. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015; 8 (3): 519-26. DOI: 10.1161/CIRCHEARTFAILURE.113.000890.
17. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012; 109: 9629-34. DOI: 10.1073/pnas.1121005109.
18. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agencyapproved drug. J Mol Biol. 2012; 421 (2-3): 185-203. DOI: 10.1016/j.jmb.2011.12.060.
19. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014; 39 (3): 225-33. DOI: 10.1111/jcpt.12145.
Review
For citations:
Gudkova A.Ya., Poliakova A.A., Amelin А.V., Moiseeva O.М., Krutikov А.N., Tishkova V.М., Grozov R.V., Ryzhkova D.V., Makurova T.V., Kostareva A.A., Semernin E.N., Shlyakhto E.V. NON-VAL30MET-TRANSTHYRETIN AMYLOID CARDIOMYOPATHY. LITERATURE REVIEW AND CLINICAL CASE. Russian Journal of Cardiology. 2018;(2):121-128. (In Russ.) https://doi.org/10.15829/1560-4071-2018-2-121-128
Views:
1524
Email this article 